Skip to main content

Newsroom

Please see below links to the most recent news and events for IDEAYA.

 

Media Contacts News Alerts LinkedIn

 
Latest Press
Nov 4, 2024

Enrollment in darovasertib + crizotinib 1L HLA-A2(-) MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patients Successful FDA Type C meeting and targeting...

Nov 1, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 31, 2024, the...

Oct 28, 2024

IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program

All News

Featured Stories
Stay up-to-date with us
GET EMAIL ALERTS
* Required Fields
Close Menu